1. Home
  2. IRD vs SNYR Comparison

IRD vs SNYR Comparison

Compare IRD & SNYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • SNYR
  • Stock Information
  • Founded
  • IRD 2018
  • SNYR 2010
  • Country
  • IRD United States
  • SNYR United States
  • Employees
  • IRD N/A
  • SNYR N/A
  • Industry
  • IRD
  • SNYR
  • Sector
  • IRD
  • SNYR
  • Exchange
  • IRD NYSE
  • SNYR NYSE
  • Market Cap
  • IRD 59.1M
  • SNYR 16.6M
  • IPO Year
  • IRD N/A
  • SNYR N/A
  • Fundamental
  • Price
  • IRD $1.12
  • SNYR $3.40
  • Analyst Decision
  • IRD Strong Buy
  • SNYR Strong Buy
  • Analyst Count
  • IRD 3
  • SNYR 1
  • Target Price
  • IRD $6.33
  • SNYR $10.00
  • AVG Volume (30 Days)
  • IRD 754.3K
  • SNYR 105.6K
  • Earning Date
  • IRD 08-15-2025
  • SNYR 08-24-2025
  • Dividend Yield
  • IRD N/A
  • SNYR N/A
  • EPS Growth
  • IRD N/A
  • SNYR N/A
  • EPS
  • IRD N/A
  • SNYR 0.30
  • Revenue
  • IRD $13,651,000.00
  • SNYR $33,592,914.00
  • Revenue This Year
  • IRD $51.41
  • SNYR $37.83
  • Revenue Next Year
  • IRD $68.84
  • SNYR $18.39
  • P/E Ratio
  • IRD N/A
  • SNYR $11.12
  • Revenue Growth
  • IRD N/A
  • SNYR N/A
  • 52 Week Low
  • IRD $0.65
  • SNYR $0.36
  • 52 Week High
  • IRD $2.18
  • SNYR $10.00
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • SNYR N/A
  • Support Level
  • IRD N/A
  • SNYR N/A
  • Resistance Level
  • IRD N/A
  • SNYR N/A
  • Average True Range (ATR)
  • IRD 0.00
  • SNYR 0.00
  • MACD
  • IRD 0.00
  • SNYR 0.00
  • Stochastic Oscillator
  • IRD 0.00
  • SNYR 0.00

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About SNYR SYNERGY CHC CORP

Synergy CHC Corp is a provider of consumer health care, beauty, and lifestyle products. It is engaged in the business of marketing and distributing consumer branded products through various distribution channels in the health and wellness industry. The company's products include FOCUSfactor, Flat Tummy Tea, Hand MD, and Neuragen amongst others. Flat Tummy is a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their nutrition and weight management goals.

Share on Social Networks: